TY - JOUR AU - Hesketh, P. J. AU - Kris, M. G. AU - Basch, E. AU - Bohlke, K. AU - Barbour, S. Y. AU - Clark-Snow, R. A. PY - 2017 DA - 2017// TI - Antiemetics: American Society of Clinical Oncology clinical practice guideline update JO - JCO. VL - 35 UR - https://doi.org/10.1200/JCO.2017.74.4789 DO - 10.1200/JCO.2017.74.4789 ID - Hesketh2017 ER - TY - JOUR AU - Berger, M. J. AU - Ettinger, D. S. AU - Aston, J. AU - Barbour, S. AU - Bergsbaken, J. AU - Bierman, P. J. PY - 2017 DA - 2017// TI - NCCN guidelines insights: Antiemesis, version 2.2017 JO - J Natl Compr Canc Netw VL - 15 UR - https://doi.org/10.6004/jnccn.2017.0117 DO - 10.6004/jnccn.2017.0117 ID - Berger2017 ER - TY - JOUR AU - Roila, F. AU - Molassiotis, A. AU - Herrstedt, J. AU - Aapro, M. AU - Gralla, R. J. AU - Bruera, E. PY - 2016 DA - 2016// TI - 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw270 DO - 10.1093/annonc/mdw270 ID - Roila2016 ER - TY - JOUR AU - Takeuchi, H. AU - Saeki, T. AU - Aiba, K. AU - Tamura, K. AU - Aogi, K. AU - Eguchi, K. PY - 2015 DA - 2015// TI - Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary JO - Int J Clin Oncol VL - 21 UR - https://doi.org/10.1007/s10147-015-0852-1 DO - 10.1007/s10147-015-0852-1 ID - Takeuchi2015 ER - TY - JOUR AU - Oo, T. H. AU - Hesketh, P. J. PY - 2005 DA - 2005// TI - Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting JO - Nat Clin Prac Oncol VL - 2 UR - https://doi.org/10.1038/ncponc0132 DO - 10.1038/ncponc0132 ID - Oo2005 ER - TY - JOUR AU - Saito, M. AU - Aogi, K. AU - Sekine, I. AU - Yoshizawa, H. AU - Yanagita, Y. AU - Sakai, H. PY - 2009 DA - 2009// TI - Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(08)70313-9 DO - 10.1016/S1470-2045(08)70313-9 ID - Saito2009 ER - TY - JOUR AU - Suzuki, K. AU - Yamanaka, T. AU - Hashimoto, H. AU - Shimada, Y. AU - Arata, K. AU - Matsui, R. PY - 2016 DA - 2016// TI - Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw220 DO - 10.1093/annonc/mdw220 ID - Suzuki2016 ER - TY - JOUR AU - Kolesar, J. M. AU - Eickhoff, J. AU - Vermeulen, L. C. PY - 2014 DA - 2014// TI - Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different? JO - Am J Health Sys Pharm VL - 71 UR - https://doi.org/10.2146/ajhp130653 DO - 10.2146/ajhp130653 ID - Kolesar2014 ER - TY - JOUR AU - Avritscher, E. B. C. AU - Shih, Y. C. T. AU - Sun, C. C. AU - Gralla, R. J. AU - Grunberg, S. M. AU - Xu, Y. PY - 2010 DA - 2010// TI - Cost–Utility Analysis of Palonosetron-Based Therapy in Preventing Emesis Among Breast Cancer Patients JO - J Support Oncol VL - 8 UR - https://doi.org/10.1016/j.suponc.2010.09.027 DO - 10.1016/j.suponc.2010.09.027 ID - Avritscher2010 ER - TY - JOUR AU - Du, Q. AU - Zhai, Q. AU - Zhu, B. AU - Xu, X. -. L. AU - Yu, B. PY - 2016 DA - 2016// TI - Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of “overall” nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients JO - J Oncol Pharm Pract VL - 23 UR - https://doi.org/10.1177/1078155216652212 DO - 10.1177/1078155216652212 ID - Du2016 ER - TY - STD TI - Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, et al. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). J Pharm Health Care Sci. 2018;4(1):31. ID - ref11 ER - TY - JOUR AU - Susan Moore, M. D. M. AU - BA, J. T. AU - Steven Wojtanowski, R. P. M. AU - Christopher Flowers, M. D. M. S. PY - 2007 DA - 2007// TI - Cost-effectiveness of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly Emetogenic chemotherapy JO - Value Health VL - 10 UR - https://doi.org/10.1111/j.1524-4733.2006.00141.x DO - 10.1111/j.1524-4733.2006.00141.x ID - Susan Moore2007 ER - TY - STD TI - Humphreys S, Pellissier J, Jones A. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res. 2013;5:215–24. ID - ref13 ER - TY - JOUR AU - Annemans, L. AU - Strens, D. AU - Lox, E. AU - Petit, C. AU - Malonne, H. PY - 2007 DA - 2007// TI - Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium JO - Support Care Cancer VL - 16 UR - https://doi.org/10.1007/s00520-007-0349-1 DO - 10.1007/s00520-007-0349-1 ID - Annemans2007 ER - TY - STD TI - National Health Insurance Drug Price Standard. Drug price standard score chart April, 2018 version. Tokyo, Japan Social Insurance Research Laboratory; 2018. ID - ref15 ER - TY - STD TI - Reimbursement Schedule of Social Insurance. Medical treatment fee score chart April, 2018 version. Tokyo, Japan Social Insurance Research Laboratory; 2018. ID - ref16 ER - TY - STD TI - Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clini Oncol. 2016;1:1–8. ID - ref17 ER - TY - JOUR AU - Oshima, Y. AU - Ban, A. PY - 2009 DA - 2009// TI - Pharmacoeconomic evaluation of low dose steroids for delayed nausea due to anticancer chemotherapy JO - J Jpn Soc Hosp Pharm VL - 45 ID - Oshima2009 ER - TY - JOUR AU - Yamanishi, Y. AU - Tajima, H. PY - 2014 DA - 2014// TI - Cost-Eectiveness Analysis of 5-HT3 Receptor Antagonist Drug: Palonosetron in Cancer Chemotherapy JO - Jpn J Pharm Palliat Care Sci VL - 7 ID - Yamanishi2014 ER - TY - JOUR AU - Sun, C. C. AU - Bodurka, D. C. AU - Weaver, C. B. AU - Rasu, R. AU - Wolf, J. K. AU - Bevers, M. W. PY - 2004 DA - 2004// TI - Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer JO - Support Care Cancer VL - 13 UR - https://doi.org/10.1007/s00520-004-0710-6 DO - 10.1007/s00520-004-0710-6 ID - Sun2004 ER - TY - JOUR AU - Lordick, F. AU - Ehlken, B. AU - Ihbe-Heffinger, A. AU - Berger, K. AU - Krobot, K. J. AU - Pellissier, J. PY - 2007 DA - 2007// TI - Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2006.09.019 DO - 10.1016/j.ejca.2006.09.019 ID - Lordick2007 ER - TY - JOUR AU - Tsukiyama, I. AU - Hasegawa, S. AU - Ikeda, Y. AU - Takeuchi, M. AU - Tsukiyama, S. AU - Kurose, Y. PY - 2018 DA - 2018// TI - Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy JO - Cancer Sci VL - 109 UR - https://doi.org/10.1111/cas.13736 DO - 10.1111/cas.13736 ID - Tsukiyama2018 ER - TY - STD TI - OECD Data. Exchange rates. https://data.oecd.org/conversion/exchange-rates.htm. Accessed 17 Aug 2018. UR - https://data.oecd.org/conversion/exchange-rates.htm ID - ref23 ER - TY - JOUR AU - Fukuda, T. AU - Shiroiwa, T. AU - Ikeda, S. PY - 2013 DA - 2013// TI - Guideline for economic evaluation of healthcare technologies in Japan. [in Japanese] JO - J Natl Inst Public Health VL - 62 ID - Fukuda2013 ER - TY - JOUR AU - Husereau, D. AU - Drummond, M. AU - Petrou, S. AU - Carswell, C. AU - Moher, D. AU - Greenberg, D. PY - 2013 DA - 2013// TI - Consolidated health economic evaluation reporting standards (CHEERS) statement JO - Clin Ther VL - 35 UR - https://doi.org/10.1016/j.clinthera.2013.03.003 DO - 10.1016/j.clinthera.2013.03.003 ID - Husereau2013 ER - TY - JOUR AU - Shiroiwa, T. AU - Sung, Y. -. K. AU - Fukuda, T. AU - Lang, H. -. C. AU - Bae, S. -. C. AU - Tsutani, K. PY - 2010 DA - 2010// TI - International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? JO - Health Econ VL - 19 UR - https://doi.org/10.1002/hec.1481 DO - 10.1002/hec.1481 ID - Shiroiwa2010 ER - TY - JOUR AU - Cawston, H. AU - Bourhis, F. AU - Eriksson, J. AU - Ruffo, P. AU - Di'Agostino, P. AU - Turini, M. PY - 2017 DA - 2017// TI - NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK JO - DIC VL - 6 UR - https://doi.org/10.7573/dic.212298 DO - 10.7573/dic.212298 ID - Cawston2017 ER - TY - JOUR AU - Restelli, U. AU - Saibene, G. AU - Nardulli, P. AU - Turi, R. AU - Bonizzoni, E. AU - Scolari, F. PY - 2017 DA - 2017// TI - Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy JO - BMJ Open VL - 7 UR - https://doi.org/10.1136/bmjopen-2016-015645 DO - 10.1136/bmjopen-2016-015645 ID - Restelli2017 ER -